Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1997 Jul;17(1):8-36.
doi: 10.2165/00002018-199717010-00002.

Adverse effects of class I antiarrhythmic drugs

Affiliations
Review

Adverse effects of class I antiarrhythmic drugs

J Caron et al. Drug Saf. 1997 Jul.

Abstract

Class I antiarrhythmic drugs are characterised by their ability to block the fast inward sodium current in cardiac muscle tissue. However, at the same time, they can be responsible for various effects involving other organs and systems. Although some of these effects can be helpful in specific situations, most of them, such as their pro-arrhythmic propensity, are deleterious. Some of the adverse effects of class I antiarrhythmic drugs are directly linked to sodium-channel blockade (conduction disorders haemodynamic perturbations, and digestive and neurological effects), while others are linked to other specific pharmacological properties (e.g. atropinic, or alpha- or beta-adrenergic blockade) or to nonspecific properties (idiosyncratic hypersensitivity, and haematological, dermatological or hepatic reactions). Other adverse effects are associated with complex interactions between class I antiarrhythmics and individual predisposing factors, trigger mechanisms and physiological factors (including concomitant drug treatment). These numerous variations and interactions within a specific environment and underlying disorder might be of pharmacological or/and pharmacokinetic origin, making analysis of the true liability of the class I drugs very difficult when adverse effects occur.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Drugs. 1993 Aug;46(2):219-48 - PubMed
    1. J Cardiovasc Pharmacol. 1989 Oct;14 (4):577-84 - PubMed
    1. Am J Med. 1990 May;88(5):512-8 - PubMed
    1. Am J Cardiol. 1985 Jul 1;56(1):84-8 - PubMed
    1. Arthritis Rheum. 1989 May;32(5):560-8 - PubMed

MeSH terms

LinkOut - more resources